Today's sweep found a supplemental filing for abrocitinib but no new dermatological approval or safety communication carrying clinical detail. The substantive guidance is a Good Practice Statement from an expert multidisciplinary workgroup, developed using GRADE methodology, on the diagnostic workup of adults with presumed atopic dermatitis that has not responded to optimised treatment.
Its core proposition is that treatment failure should trigger diagnostic reassessment rather than automatic escalation, because in this group misdiagnosis or a concomitant condition is often what is actually driving the failure. Cutaneous T-cell lymphoma, allergic contact dermatitis, scabies and psoriasis all masquerade as refractory eczema, and each has a different treatment.
The workgroup is unusually candid about its own limitations, and that candour is worth passing on: direct empirical evidence on diagnostic workup strategies for treatment-resistant atopic dermatitis does not exist, so this rests on indirect evidence and expert consensus. It also notes applicability depends on access to dermatology and allergy specialist care, which is the binding constraint in most of the world. As a prompt to stop and re-examine before adding a third systemic agent, it is sound regardless of setting.
- No new dermatology approval with clinical detail; one abrocitinib supplement
- Treatment failure should trigger diagnostic reassessment, not automatic escalation
- Consider cutaneous T-cell lymphoma, contact dermatitis, scabies and psoriasis
- Based on indirect evidence and consensus; direct data do not exist
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free